29 results
8-K
EX-10.1
VRNA
Verona Pharma Plc
2 Jan 24
Strengthens financial flexibility to support the Company’s continued growth
6:02am
of Borrower, and the reasonable expenses of investigation by engineers, environmental consultants and similar technical personnel and any commission, fee
8-K
EX-10.1
rkb mub1vo28p
17 Oct 22
Entry into a Material Definitive Agreement
6:00am
8-K
EX-1.1
gw8our
11 Aug 22
Other Events
5:46pm
S-3
EX-1.2
bwbpyn1r
19 Mar 21
Shelf registration
5:23pm
DEF 14A
wm1gspv6
19 Mar 21
Definitive proxy
4:02pm
10-K
8x1lpdinrf54 4mhg8c
25 Feb 21
Annual report
8:29am
F-1/A
jv1xb6p1tpbash k0
25 Aug 20
Registration statement (foreign) (amended)
4:06pm
F-1
sunhdrjpyu7 ig9
17 Aug 20
Registration statement (foreign)
6:41am
D
833fj8iy4r4r1 br2
30 Jul 20
$200.16M in equity, sold $200.16M, 43 investors
12:00am
6-K
EX-1
m9d fy0ez467knv
22 Jul 20
Current report (foreign)
4:05pm